Upper gastrointestinal cancers have overtaken lung cancer to become the leading cause of cancer-related deaths in Australia for the first time, according to new analysis of national mortality data. This shift, revealed by research from the Pancare Foundation and analysts Provocate, marks a significant change in Australia's cancer landscape that few Australians seem aware of.
The data presents a striking picture.Research by the Pancare Foundation and analysts Provocate found upper GI cancers were responsible for 9,301 deaths in 2024. That represents about 18 per cent of all cancer deaths nationally.Lung cancers, which held the unwanted record for decades, accounted for 9,119 deaths, or around 17 per cent. The difference is narrow, but the direction of movement is clear.
What the data actually tells us is that this group of diseases is accelerating at an alarming rate.Between 2014 and 2024, fatalities linked to the cancers increased by 35 per cent. That growth in death rate is roughly double the increase recorded across all cancers combined, which rose by 18 per cent during the same period.Over longer timeframes, the research also identified upper GI cancers as the fastest growing tumour stream in Australia across five, 10 and 20 years.
Upper GI cancers include pancreatic, liver, stomach, oesophageal and biliary cancers, a group of diseases affecting the digestive system that often develop without obvious early warning signs and can be difficult to diagnose quickly. Each presents its own clinical challenges.Stomach and oesophageal cancers have a disproportionally high mortality rate compared to the average 5-year overall survival for all cancers combined (at 71.2%), with 5-year overall survival rates of 38 per cent and 23 per cent respectively. Pancreatic cancer is even more grim.In 2017 to 2021, individuals diagnosed with pancreatic cancer had a 14 per cent chance of surviving for five years compared to their counterparts in the general Australian population.
The clinical significance here is profound. These are not slow-growing cancers detected by routine screening.Early stages of pancreatic cancer do not usually produce symptoms, so it is generally advanced when it is diagnosed. When symptoms do appear, they are frustratingly nonspecific. Patients report heartburn, indigestion, stomach pain, unexplained weight loss, difficulty swallowing, and jaundice. These could describe dozens of common conditions. By the time a diagnosis is made, the cancer often has spread beyond the reach of surgery.
Perhaps most troubling is what the polling reveals about public understanding.Polling conducted for the analysis showed only two per cent of Australians correctly identified upper GI cancers as the cancer group responsible for the most deaths. Instead, 21 per cent believed lung cancers were the leading cause of cancer deaths. This awareness gap matters. When people do not understand which cancers pose the greatest threat, public health messages, research funding, and clinical attention drift elsewhere.
The resource question is pressing.Upper GI cancers are now responsible for nearly one in five cancer deaths but have received less than one in 10 cancer research dollars in Australia in recent years. This disparity between mortality burden and research funding represents a genuine misalignment of resources relative to need. For context,the number of interventional clinical trials that are active or recruiting for pancreatic cancer in Australia is significantly lower than for prostate and breast cancer.
Before drawing conclusions about what should change, several caveats apply. The ageing population naturally shifts cancer patterns. Older Australians develop more of all cancers, including upper GI types. Whether the 35 per cent increase in deaths reflects genuine acceleration in disease rates or partly reflects demographic change requires careful analysis. Additionally, changes in survival from other cancers (particularly lung cancer, where smoking prevalence has fallen) mean lung cancer deaths have grown more slowly, creating relative shifts even if absolute trends differed.
What patients need to know is this: if you experience persistent heartburn, indigestion that does not respond to simple treatment, ongoing stomach pain, unexplained weight loss, or difficulty swallowing, seek medical advice.More than 80 per cent of patients report at least one red-flag symptom or sign that is predictive of underlying gastro-oesophageal cancer. The presence of these red-flag symptoms without a clear explanation should prompt consideration for endoscopic and gastrointestinal specialist referral. Early referral matters.Data from a UK study indicate that nearly a quarter of all patients with any symptoms received three or more consultations with their general practitioner before a hospital referral. Another UK study found that this often amounts to more than 90 days delay in reaching a cancer diagnosis.
Australia's deadliest cancer has quietly changed. The shift reflects not just epidemiological reality but also a gap between disease burden and the attention, funding, and awareness these cancers receive. Closing that gap requires honest conversation about where research dollars go, how quickly specialists are accessed, and whether general practitioners feel confident recognising warning signs. The data is clear. The question now is whether the health system will respond accordingly.